Browsed by
Tag: heart disease

Google Life Sciences to Fund Heart Disease Program – Article by Reason

Google Life Sciences to Fund Heart Disease Program – Article by Reason

The New Renaissance Hat
Reason
November 22, 2015
******************************

An interesting next step from Google Life Sciences: they are putting forward $50 million in search of a laboratory to propose a program that pushes forward the state of the art in research and treatment of heart disease. Spent over ten years, that would produce an organization about the present size of the SENS Research Foundation, or a tenth of the Buck Institute, for purposes of comparison – and smaller than many of the research groups presently dedicated to the study of heart disease. So this is a sizable and welcome investment in medical research, but the significance is overhyped by the reporting organization here; no-one is going to cure heart disease with a $50 million project, since heart disease is caused by aging, and in the most general sense. This is an effort to change the funding landscape, stir things up, and make some progress.

If you walk through the list of forms of cell and tissue damage that causes degenerative aging, near every one of them contributes to structural failure of the cardiovascular system. The loss of stem cell activity and consequent decline in repair of tissues is only one of these: oxidized lipids that contribute to atherosclerosis in blood vessel walls; extracellular cross-links stiffen blood vessel walls and cause hypertension and consequent structural weakening in the heart; senescent cells wreck havoc on all the tissues they accumulate in; transthyretin amyloids that accumulate with age are implicated in heart disease via their ability to clog the cardiovascular system; and the loss of lysosomal function in long-lived cells, including those of the heart, progressively damages their function. Curing heart disease, removing it from the picture, requires treatments that effectively address near all of the causes of aging.

Quote from “Google Aims a $50 Million Moonshot at Curing Heart Disease” by Davey Alba, WIRED, November 16, 2015:

Cardiovascular disease people on Earth than anything else – over 17 million a year, and the number keeps going up. Of those deaths, more than 40 percent is due to coronary heart disease. Medicine has drugs that can treat it and practices that can help prevent it, but nobody really knows what causes it or how to cure it. Now, Google and the American Heart Association aim to change that by dropping a $50 million funding bomb on the problem. And as you might expect from a Silicon Valley giant that believes in moving fast and breaking things – an approach that hasn’t always transferred well to basic scientific research – the company isn’t spreading the money around. Google Life Sciences and the AHA said the money would go to one team over five years. “Traditional research funding models are often incremental and piecemeal, making it difficult to study a long-term, multifaceted subject. AHA and Google Life Sciences have committed to a bold new approach.”

The AHA, already the largest funder of cardiovascular research in the US outside of the federal government, says the program will be its most heavily funded initiative in nearly a century. Applications begin in January and if all goes according to plan, they’ll be due by February 14th. (Valentine’s Day. Get it?) If you want the $50 million, your idea has to fit on a single page. And Google won’t take a financial or intellectual property stake in the results. The organizations hope that the program will accelerate the field of heart research much like Google’s self-driving car eventually compelled the entire automobile industry to follow its lead.

Link: http://www.wired.com/2015/11/google-aims-a-50-million-moonshot-at-curing-heart-disease/

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries. 
***

This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.

BioViva Treats First Patient with Gene Therapy to Reverse Aging – Press Release by Elizabeth Parrish

BioViva Treats First Patient with Gene Therapy to Reverse Aging – Press Release by Elizabeth Parrish

The New Renaissance HatElizabeth Parrish
October 3, 2015
******************************

BioViva USA, Inc. has become the first company to treat a person with gene therapy to reverse biological aging, using a combination of two therapies developed and applied outside the United States of America. Testing and research on these therapies is continuing in BioViva’s affiliated labs worldwide.

BioViva CEO Elizabeth Parrish announced that the subject is doing well and has resumed regular activities. Preliminary results will be evaluated at 5 and 8 months with full outcome expected at 12 months. The patient will then be monitored every year for 8 years.

Gene therapy allows doctors to treat disease at the cellular level by inserting a gene into a patient’s cells instead of using the regular modalities of oral drugs or surgery. BioViva is testing several approaches to age reversal, including using gene therapy to introduce genes into the body.

Although not generally considered a disease, cellular aging is the leading cause of death in the developed world. Side effects like muscle wasting (sarcopenia), grey hair and memory loss are the well-known hallmarks.

And the aging cell is also responsible for the diseases of aging, including Alzheimer’s disease, heart disease and cancer. BioViva is leading the charge to treat the aging cell and reverse aging. “The aging cell is a key factor that has been overlooked for too long. Companies have put millions of dollars into treating the diseases of aging, such as dementia, frailty, kidney failure and Parkinson’s disease, and we still do not have a cure,” says Parrish.

Until now, no company had tried multiple gene therapies in one person. When asked why BioViva has done so, Parrish says, “Aging involves multiple pathways. We wanted to target more than one for a better outcome.”

Contact
Elizabeth Parrish
lparrish(at)BioVivaSciences(dot)com
http://www.biovivasciences.com

Elizabeth Parrish, CEO of BioViva, is a humanitarian, entrepreneur, and innovator, and is a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA), which is a unique platform for Mensa-based, highly gifted persons who advance scientific discourse and discovery.

The mission of the CBSA is to further scientific understanding of biological complexity and the nature and origins of human disease. Elizabeth is the founder of BioTrove Investments LLC and the BioTrove Podcasts, which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine.  She is also the Secretary of The American Longevity Alliance (ALA), a 501(c)(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular and regenerative medicine.

Editor’s Note: Elizabeth Parrish also made the announcement of this promising human trial at the October 1, 2015, Movement for Indefinite Life Extension (MILE) panel discussion “How Can Life Extension Become as Popular as the War on Cancer?” Watch the discussion here.

~ Gennady Stolyarov II, Editor-in-Chief, The Rational Argumentator, October 3, 2015